CVRx Inc
$ 7.72
-1.15%
14 Apr - close price
- Market Cap 205,494,000 USD
- Current Price $ 7.72
- High / Low $ 8.48 / 7.69
- Stock P/E N/A
- Book Value 1.50
- EPS -2.04
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.97 %
- 52 Week High 11.30
- 52 Week Low 4.30
About
CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.
Analyst Target Price
$11.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-22 | 2025-11-04 | 2025-08-04 | 2025-05-08 | 2025-02-04 | 2024-10-29 | 2024-07-29 | 2024-04-30 | 2024-01-25 | 2023-10-26 | 2023-07-25 | 2023-04-27 |
| Reported EPS | -0.46 | -0.49 | -0.57 | -0.53 | -0.43 | -0.57 | -0.65 | -1.04 | -0.44 | -0.43 | -0.56 | -0.55 |
| Estimated EPS | -0.4446 | -0.5 | -0.52 | -0.57 | -0.38 | -0.47 | -0.55 | -0.54 | -0.54 | -0.58 | -0.58 | -0.56 |
| Surprise | -0.0154 | 0.01 | -0.05 | 0.04 | -0.05 | -0.1 | -0.1 | -0.5 | 0.1 | 0.15 | 0.02 | 0.01 |
| Surprise Percentage | -3.4638% | 2% | -9.6154% | 7.0175% | -13.1579% | -21.2766% | -18.1818% | -92.5926% | 18.5185% | 25.8621% | 3.4483% | 1.7857% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.51 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CVRX
2026-04-14 17:09:28
Canaccord Genuity has reiterated a 'Buy' rating for CVRx (CVRX), maintaining a steady price target of $10.00, indicating confidence in the company's growth potential. GuruFocus assesses CVRx as significantly undervalued with a GF Value™ of $13.61 against a current price of $8.28, despite a "Possible Value Trap" warning due to low profitability. Insider buying activity further supports a positive outlook, yet investors are advised to exercise caution.
2026-04-13 18:39:23
CVRx announced its preliminary first-quarter 2026 revenue, projecting it to be between $14.7 million and $14.8 million. This figure falls short of the analyst consensus estimate of $15.5 million. The company released these results ahead of its expectations.
2026-04-13 17:39:23
William Blair has reiterated an Outperform rating on CVRx Inc. (NASDAQ:CVRX) after the company announced strong preliminary first-quarter results, projecting sales significantly above consensus estimates and a healthy gross margin. Despite a miss on EPS for Q4 2025, the company beat revenue expectations, showing 4% year-over-year growth. Management expresses confidence in the company's capital access and long-term growth driven by a revamped commercial strategy, even as Canaccord Genuity lowered its price target due to sector-wide multiple decline.
2026-04-13 11:39:23
CVRx, Inc. announced preliminary unaudited first-quarter 2026 financial results, projecting revenue between $14.7 million and $14.8 million, a 20% increase from Q1 2025. The company highlights improved 30-day approval rates for Medicare Advantage prior authorizations due to new Category I CPT codes and the activation of the first site in its BENEFIT-HF clinical trial, which aims to expand the Barostim patient population. These positive developments are attributed to investments made in 2025 and are expected to drive continued momentum.
2026-04-13 11:39:16
CVRx, Inc. announced preliminary unaudited financial and operating results for the first quarter of 2026, with anticipated revenue between $14.7 million and $14.8 million, marking approximately 20% growth year-over-year. The company reported positive impacts from a new Category I CPT Code, leading to improved prior authorization approval rates for Medicare Advantage. Additionally, CVRx activated the first site for its BENEFIT-HF clinical trial, expected to significantly expand the eligible patient population for its Barostim device if successful.
2026-04-13 11:39:16
CVRx (NASDAQ: CVRX) reported preliminary Q1 2026 financial results, with revenue expected to be between $14.7 million and $14.8 million, marking a 20% growth year-over-year. The company also noted an improvement in Medicare Advantage 30-day prior authorization approval rates, reaching 50% for January-February 2026, up from 44% in 2025. Additionally, CVRx activated the first site for its BENEFIT-HF clinical trial, which aims to expand the indicated patient population for its Barostim device.
